Lexon

Lexon is a South Korean biotechnology company focused on the discovery and development of first-in-class small molecule therapeutics for oncology. The company's research centers on the Translationally Controlled Tumor Protein (TCTP), a key regulator of cell survival and anti-apoptotic pathways that is frequently overexpressed in various cancers. By developing potent TCTP inhibitors, Lexon aims to provide novel treatment options for solid tumors, including breast, lung, and prostate cancers. Their lead research programs involve the optimization of small molecule candidates designed to disrupt TCTP activity and induce cancer cell death.